Crewe Advisors’s Royalty Pharma RPRX Stock Holding History

Crewe Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-176	Closed	-$6.34K	–	983
2023 Q1	$6.34K	Hold	176	–	–	﹤0.01%	609
2022 Q4	$6.96K	Sell	176 -85	-33%	-$3.55K	﹤0.01%	613
2022 Q3	$10K	Hold	261	–	–	﹤0.01%	673
2022 Q2	$11K	Buy	+261	New	+$10.7K	﹤0.01%	574

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crewe Advisors's RPRX Position: Q2 2023 in Review

Crewe Advisors sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 176 shares — an estimated $6.34K sold.

Crewe Advisors first reported a position in RPRX in Q2 2022 and held it in 4 quarters. The position peaked at $11K in Q2 2022. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Crewe Advisors reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 176 Royalty Pharma shares in Q2 2023, an estimated $6.34K.
Crewe Advisors first reported a position in Royalty Pharma in Q2 2022 and held it in 4 quarters.
Crewe Advisors's Royalty Pharma position peaked at $11K in Q2 2022.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.